Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
    4.
    发明申请
    Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion 审中-公开
    红心肌细胞壁骨架制备过程及其治疗用于治疗子宫颈侵蚀

    公开(公告)号:US20060127518A1

    公开(公告)日:2006-06-15

    申请号:US10525849

    申请日:2003-09-05

    IPC分类号: A61K35/74

    CPC分类号: A61K35/74

    摘要: This invention relates to a biological preparation, especially Nocardia Rubra cell wall skeleton preparation. After cultivating, collecting thallus, cell fragmentation, purifying enzyme, removing the grease, the final preparation containing Nocardia Rubra cell wall skeleton is obtained by dispensing, lyophilizing and filling. The invented preparation has marked effect to adaptable diseases, healing rate is 88%, total validity rate is 100%. This external preparation shows harmless, safe, non-toxicity and easy to be used with little side effect and lower cost.

    摘要翻译: 本发明涉及生物制剂,特别是诺卡氏菌Rubra细胞壁骨架制剂。 培养后,收集细胞,细胞破碎,纯化酶,去除油脂,通过分配,冻干和灌装获得含有诺卡氏菌Rubra细胞壁骨架的最终制剂。 本发明制剂对适应性疾病有显着疗效,愈合率为88%,总有效率为100%。 该外用制剂显示无害,安全,无毒,易于使用,副作用少,成本低。

    Oral treatment for anorectal conditions
    5.
    发明申请
    Oral treatment for anorectal conditions 审中-公开
    口腔治疗肛门直肠病

    公开(公告)号:US20050053682A1

    公开(公告)日:2005-03-10

    申请号:US10658194

    申请日:2003-09-10

    CPC分类号: A61K36/75

    摘要: Methods and uses pertaining to the oral treatment of anorectal conditions in a man or woman in need of such treatment are described, which comprises treatment with an orally effective amount of an extract of Cortex Dictamni in unit dosage form in association with one or more carriers or excipients.

    摘要翻译: 描述了与需要这种治疗的男性或女性口腔治疗肛门直肠病症有关的方法和用途,其包括以口服有效量的单位剂量形式的皮质硬脑膜炎提取物与一种或多种载体或 赋形剂。

    AI-BASED MODEL USE FOR NETWORK ENERGY SAVINGS

    公开(公告)号:US20230138190A1

    公开(公告)日:2023-05-04

    申请号:US18091673

    申请日:2022-12-30

    IPC分类号: H04W52/02 H04W36/24

    摘要: An apparatus and system of providing energy saving in a network are described. A target node receives, from a source node, a handover request to handover a UE due to at least one of entry of the source node into a power saving state or mobility optimization. In response, the target node transmits a relative energy efficiency value of Bits per Joule and periodic feedback related to a status of the UE for training an AI/ML energy saving model and stops the feedback in response to a stop parameter being met. The stop parameter is a first of: a predicted period of the source node to stay in the power saving state or time for a UE to connect to the target node, a percentage of UEs handed over that enter an idle or inactive state, and a percentage of UEs handed over that are further handed to another node.

    ULTRASOUND SYSTEM, APPARATUS, AND METHOD FOR TRANSCRANIAL TREATMENT

    公开(公告)号:US20230015807A1

    公开(公告)日:2023-01-19

    申请号:US17859542

    申请日:2022-07-07

    申请人: Yi Zhang

    发明人: Yi Zhang

    IPC分类号: A61N7/02

    摘要: The present disclosure relates to transcranial ultrasound systems, devices, and methods which are used for treatment rather than for imaging or medical diagnosis. In accordance with one aspect, a system for applying ultrasound energy includes at least three ultrasound applicators configured to be secured against a head of a person and configured to apply ultrasound energy to the head of the person when activated, and a controller configured to control activation and deactivation of the at least three ultrasound applicators based on a predetermined treatment sequence.

    Heart failure detection with a sequential classifier

    公开(公告)号:US10893824B2

    公开(公告)日:2021-01-19

    申请号:US13306343

    申请日:2011-11-29

    申请人: Qi An Yi Zhang

    发明人: Qi An Yi Zhang

    摘要: A system and method for automatically analyzing heart failure in a patient, including collecting physiological data from a patient using at least a first sensor and a second sensor to collect two or more sensor measurements, and calculating a first composite value based on at least a first sensor measurement wherein the first composite value is an indication of a likelihood that the patient's heart failure status has changed. If the first composite value is outside of a first specified range, then a second composite value is calculated based on at least a second sensor measurement, wherein the second composite value is an indication of a likelihood that the patient's heart failure status has changed. If the second composite value is outside of a second specified range, then an alert of change in heart failure status is generated.